Affera brings to Medtronic its Affera Prism-1 cardiac mapping and navigation platform, the Arc-10 Linear coronary sinus catheter and the Sphere-9 cardiac ablation catheter, which offers both focal ablation therapy and HD mapping capabilities. The addition of these technologies is expected to bolster Medtronic’s atrial and ventricular arrhythmia disease management portfolio.

Affera also just closed a $75 million Series C financing round in December, according to the Star Tribune. That same month, it commenced its SPHERE PerAF Trial. The FDA investigational Device Exemption (IDE) pivotal randomized trial will evaluate the safety and effectiveness of the Affera system for the treatment of persistent AF.


“This acquisition directly aligns with our vision of delivering novel solutions to address the rapidly growing demands for cardiac arrhythmia treatment,” said Doron Harlev, founder and chief executive officer of Affera.

Affera’s product portfolio is not currently approved or available for sale or commercial use.

The acquisition is expected to close in the first half of Medtronic’s fiscal year 2023, which begins May 1, according to the Star Tribune. The deal is subject to certain customary closing conditions. The transaction is expected to be less than 1% dilutive to Medtronic’s adjusted earnings per share in each of the first three years, and neutral to accretive thereafter.

Back to HCB News

Business Affairs Homepage